Webinars

Webinars

Humanized M-NSG PBMC and CD34+ Mouse Models 2023

Applied StemCell now supplies research-ready humanized PBMC and CD34+ reconstruction mouse models ideal for infectious disease, gene therapy, hematopoiesis, drug target, and immunogenicity studies. Our humanized models are generated using our M-NSG mice through the injection of healthy human donor peripheral blood mononuclear cells (PBMCs) or CD34+ hematopoietic stem cells (HSCs). After a few weeks of reconstruction following the injection of PBMCs or CD34+ HSCs, the mice develop a human-like immune system and are ready to be shipped.

Topics covered in this video:

• The important role of our specific immune deficient M-NSG mice in research

• Overview of humanization approaches using PBMCs and HSCs

• Discussion of the use of our specific immune deficient M-NSG mice

• Applications of humanized mice in immuno-oncology research

• Potential for developing effective immunotherapies using humanized mouse models

Thumbnail_Webinar_Humanized M-NSG PBMC and CD34+ mousemodel-20230421


Advancing Gene and Cell Therapy Through iPSC and Genome Editing Technologies

Applied StemCell’s brings its several years of experience and expertise in genome editing and stem cell technologies to provide custom service to advance preclinical stage gene and cell therapy projects. From generating preclinical proof-of-concept cell line and animal models and assay development, to potency, efficacy and safety assessments, all the way to CMC consultation for vector and cell line manufacturing, Applied StemCell’s technology platforms will pave the way for a smooth screening of your cell and gene therapy candidates to enable IND-filing.

Topics covered in this video:

• Quality management and data security

• Focus areas in cell and gene therapy: preclinical, clinical and manufacturing

• ASC’s Core technology and positioning as a cell and gene therapy CRO

• Gene therapy and preclinical assay development capabilities: model generation, optimizing constructs, efficacy studies, AAV infectivity, potency assay, toxicology studies, and stability

• iPSCs for assay development: patient-derived cells, iPSC gene editing, iPSC differentiation, drug efficacy and toxicity screening

• COVID 19 support: Humanized ACE2 mouse model for SARS-CoV2 research and therapeutic development

webinar-2020-bioservce-ruby


TARGATT™ Rapid and Efficient Transgene Integration Technology: Stable Cell Line Development and Generation of Large Mammalian Cell-based Screening Libraries

Applied StemCell’s TARGATT™ site-specific transgene knockin technology provides a very efficient platform for stable cell line generation and for mammalian cell-based library screening. Based on our very successful TARGATT™ transgenic mouse model generation platform, the TARGATT™ cell line generation involves the generation of TARGATT™ Master Cell Lines that are engineered to carry an integrase recognition landing pad, “attP” in a preselected, intergenic, safe harbor locus. The TARGATT™ integrase then mediates a unidirectional recombination between the attP sites in the cell line and attB sites on the donor plasmid to integrate the gene of interest into the specified locus with very high efficiency (which translates to library sizes) and more importantly only one copy of the gene is inserted.

Topics covered in this short video:

  • Importance of mammalian screening libraries and advantages of integrase for transgene insertion
  • TARGATT™  technology for site-specific gene knockin
  • TARGATT™ Master Cell Line for transgene knockin
  • Evaluation of various docking site (landing pad) loci for high level protein expression
  • Expression of a Fc fusion protein
  • Potential applications for the TARGATT™ mammalian library screens

webinar-targatt-libraryscreen-xiuling


iPSC Genome Editing Rapid Automated Cell Line Editing (RACE™)

This short webinar highlights Applied StemCell’s (ASC) highly acclaimed, stem cell genome editing service to generate physiologically relevant in vitro models using iPSCs and CRISPR/ Cas9. The video showcases our ability to induce or correct mutation with standard genetic modifications (such as knockout, knock-in, and point mutation) as well as complex genome engineering such as gene fusion. Furthermore, our high throughput automated process enables higher volume projects, better picking accuracy, reduced hands-on time and errors leading up to 60% faster project timelines and 98% success rate. Applied StemCell also offers master cell lines with proven genome editing and differentiation capacity, and downstream differentiation to many cell lineages.

Topics covered in this short video:

  • Integrated end-to-end-solutions for iPSC related projects
  • Isogenic cell line model development
  • High throughput genome editing with automation and workflow optimization
  • Examples of gene modifications in patient and healthy iPSCs
  • Downstream differentiation to various lineages

supporting-material-webinar-ipsc-genomediting-short


How-to Guide for TARGATT™ Transgenic Kit, by Dr Ruby Chen-Tsai

The TARGATT™ Transgenic Kit is designed to create site-specific knock-in transgenic mice at a defined chromosomal locus in a more efficient and significantly faster way over traditional methods. Generating transgenic mice by conventional methods (e.g. pronuclear microinjection or lentiviral injection) has following limitations, first of which is random insertion of the transgene. Random insertion of a transgene results in position effect where either the transgene is prone to silencing or endogenous gene expression is disrupted. Secondly, transgenes can be inserted as multiple copies, resulting in instability at the insertion locus. Using our proprietary site-specific DNA integration system, TARGATT™, combined with our genetically engineered TARGATT™ mice (strain code 549), you can generate your desired trangenic mouse models with guaranteed gene expression in as little as three months.

This video gives a step-by-step overview on how to use the TARGATT™ Trangenic Kit and the TARGATT™ technology to generate site-specific knock-in mouse models.

WEBINAR-TARGATT™-Howto-guide


Human iPSC-based Disease Modeling & Drug Screening for Neurodegenerative Disorders

Human induced pluripotent stem cell (iPSC) technology offers the benefits of a cell line coupled with the advantage of using human primary cells. Additionally, iPSCs are also amenable to genome editing, and engineered iPSCs and their isogenic control lines can be terminally differentiated into cells of multiple lineages. This presents an almost limitless access to relevant and predictive disease models for basic research, drug discovery, toxicity screening and hopefully for regenerative cell therapy. In this webinar, we will elaborate on a panel of iPSC lines engineered for neurotoxicity assays and disease modeling. The cell lines in this panel include: 1) control lines, 2) patient-specific lines, 3) lineage-specific knock-in reporters, 4) isogenic controls of single and double knock-outs. We have also established scalable protocols for generating differentiated cells in an assay ready format. This talk will focus on the utility of these lines for neurotoxicity assays, including assays to determine the specificity of different neural cell types for a small range of chemicals and drugs from the Tox21 library, as well as for neuroprotective assays with dopaminergic neurons.

Highlights of this webinar:

WEBINAR-iPSC-neural-Xianmin


Choosing the Right Genome Editing Technology for Your Mouse ModelsCRISPRTARGATT™ and Beyond... 

Highlights of this Webinar:

2017-webinar-mousemodel


Using autobioluminescent cells to reduce the cost and complexity of optical imaging

Autobioluminescent cells use a genetically encoded synthetic luciferase cassette to continuously produce a bioluminescent signal without the need for extracellular stimulation. By encoding both a luciferase protein, as well as a short synthetic pathway capable of transforming natural intracellular products into luciferin substrates, these cells can self-modulate their bioluminescent production in response to metabolic activity levels, or autonomously enact their bioluminescent phenotype in response to intra- or extracellular events. The use of this self-directed approach to bioluminescent imaging improves upon traditional reporters such as firefly luciferase (luc) by negating the need for light activating chemical substrate addition, which reduces the cost of performance while simultaneously increasing the amount of data that can be obtained per run. This eliminates the need for sample destruction or any investigator interaction, allowing for ultra-simplistic, low-cost bioluminescent screening using existing optical imaging equipment. This webinar will discuss the capabilities and uses of autobioluminescent cells for improving existing bioluminescent imaging workflows and for developing new workflows that leverage the autonomous signal generation phenotype to gather data not available from traditional optical imaging reporter platforms.

Highlights of this webinar:

  • An introduction to autobioluminescence
  • Autobioluminescent vs. bioluminescent imaging
  •  Using autobioluminescence for in vitro applications
  •  Using autobioluminescence for in vivo applications
  •  Autobioluminescent expression in stem cells
  •  Conclusions

2016-autobioluminescence-webinar


Generating Site-specific Transgenic Rat Models using TARGATT™

This webinar introduces the TARGATT™ integrase based technology for generation of transgenic rats. The TARGATT™ platform enables very efficient insertion of large fragment DNA into a preselected, transcriptionally active locus in the rat genome. The webinar also discusses the advantages of generating transgenic rat models using this technology and the various applications that these rat models can be used in.

Highlights of the talk:

  • Introduction to TARGATT™ integrase based technology
  • How TARGATT™ technology is used to generate large fragment knock-in animal models
  • Advantages of using TARGATT™ for site-specific knock-in compared to other gene editing technologies
  • How we generate transgenic rat models using the TARGATT™ platform

2016-TARGATT™-rat-webinar


TARGATT™ and CRISPR/Cas9 modified induced pluripotent stem cells (iPSCs) for in vitro genetic disease modeling

Applied StemCell is one of the prominent providers of gene editing services to generate transgenic animal and cellular models for researchers in academia and industries. This recorded presentation showcases Applied StemCell’s achievements with using CRISPR/ Cas9 and its proprietary TARGATT™ gene editing technologies to modify induced Pluripotent Stem Cells (iPSCs). The webinar also explains the need for better models of human diseases and the advantages of using of genetically engineered iPSCs as in vitro models for genetic disease modeling. With examples and case studies, we describe how we optimize protocols to improve efficiency and are able to provide high quality service for generating iPSC disease models.

Highlights of this talk:

  • Current trends in genetically modified iPSCs as disease models
  • ASC’s complementary technology platforms (CRISPR & TARGATT™) used for generating site-specific, genetically modified iPSC models
  • Advantages of using genetically modified iPSCs and bottlenecks in gene editing of iPSCs
  • ASC’s upgraded protocols for high efficiency gene editing in iPSCs
  • Examples of gene modification from patient/ healthy individual derived iPSCs

2015-iPSC-disease-modeling


TARGATT™ Webinars:

 youtube icon TARGATT™: A Mammalian System for Antibody/ Protein Library Screening 

youtube icon  How-to Guide for TARGATT™ Transgenic Kit 
youtube icon Choosing the Right Genome Editing Technology for Your Mouse Models: CRISPR, TARGATT™ and Beyond…

MTA Agreement

Material Transfer Agreement

IMPORTANT! PLEASE READ CAREFULLY BEFORE SUBMITTING AN ORDER. THIS IS A CONTRACT.

This Material Transfer Agreement (“MTA”) is between you (“Purchaser”) and the Applied StemCell, Inc. a California company, having its principal place of business at 521 Cottonwood Drive Suite 111, Milpitas, CA 95035 USA (“ASC”). Purchaser must have an approved, current ASC account to place an order. This MTA is effective for a period of five (5) years as of the last date of execution by the parties and governs the purchase and use of all ASC Materials under the terms and conditions set forth below.

TERMS AND CONDITIONS

Definitions

“ASC Material(s)” means materials acquired from ASC as documented on an ASC Sales Order, such as iPS Cell lines.

"ASC Sales Order" means an order submitted for ASC Materials in a form and format as determined by ASC from time to time. "Biological Material(s)" means ASC Materials, Progeny, Unmodified Derivatives and Modifications, either individually or jointly. "Commercial Use" means the sale, license, lease, export, transfer or other distribution of the Biological Materials to a person or entity not party to this MTA for financial gain or other commercial purposes and/or the use of the Biological Material: (a) to provide a service to a person or entity not party to this MTA for financial gain; (b) to produce or manufacture products for general sale or products for use in the manufacture of products ultimately intended for general sale (c) in connection with ADME (Absorption, Distribution, Metabolism and Excretion) testing; (d) in connection with drug potency or toxicity testing (e) in connection with proficiency testing service(s), including but not limited to, providing the service of determining laboratory performance by means of comparing and evaluating calibrations or tests on the same or similar items or materials in accordance with predetermined conditions; or (f) for research conducted under an agreement wherein a for-profit entity receives a right whether actual or contingent to the results of the research. Commercial Use specifically does not include Industry Sponsored Academic Research.

“Contributor(s)” means an organization(s) and/or individual(s) providing original material to ASC for deposit.

"Industry Sponsored Academic Research" means research sponsored by a for-profit organization carried out at a non-profit organization and by the non-profit organization’s employees. "Investigator" means the Purchaser’s principal scientist or researcher using the Biological Material(s). "Modification(s)" mean substances created by Purchaser which contain and/or incorporate a significant or substantial portion of ASC Material. "Progeny" means an unmodified descendant from the ASC Materials, such as virus from virus, cell from cell, or organism from organism. "Purchaser(s)" means the organization purchasing and receiving ASC Material pursuant to this MTA. "Unmodified Derivative(s)" mean substances created by Purchaser that constitute an unmodified functional sub-unit or product not changed in form or character and expressed by the ASC Material provided by ASC. Unmodified Derivatives include, but are not limited to, subclones of unmodified cell lines, purified or fractionated subsets of materials provided by ASC, proteins expressed by DNA/RNA supplied by ASC, or monoclonal antibodies secreted by a hybridoma cell line.

Scope of Use

Subject to the terms of this MTA, Purchaser’s Investigator may make and use the Biological Materials provided to Purchaser by ASC for research purposes only in Purchaser’s Investigator’s laboratory only. The Biological Materials are not intended for use in humans. Purchaser agrees that Biological Materials designated as biosafety level 2 or 3 constitute known pathogens and that other Biological Materials not so designated may be pathogenic under certain conditions. Purchaser assumes all risk and responsibility in connection with the receipt, handling, storage, disposal, transfer and Purchaser’s use of the Biological Materials including without limitation taking all appropriate safety and handling precautions to minimize health or environmental risk. Purchaser agrees that any activity undertaken with the Biological Materials will be conducted in compliance with all applicable guidelines, laws and regulations, and that Purchaser will obtain all permits, licenses or other approvals required by any governmental authority in connection with purchaser’s receipt, handling, storage, disposal, transfer and use of the Biological Materials.

Purchaser shall not distribute, sell, lend or otherwise transfer to a person or entity not party to this MTA the Biological Material, as defined above, for any reason, without ASC’s prior written agreement.

Any Commercial Use of the Biological Material is strictly prohibited without ASC’s prior written consent. Purchaser acknowledges and agrees that Purchaser’s use of certain Biological Material may require a license from a person or entity not party to this MTA, or be subject to restrictions that may be imposed by a person or entity not party to this MTA (“Third Party Terms”). To the extent of ASC’s knowledge of the existence of any such applicable rights or restrictions, ASC will take reasonable steps to identify the same, either in ASC’s catalog of ASC Materials and/or through ASC’s customer service representatives, and to the extent they are in the possession of ASC, ASC shall make information regarding such Third Party Terms reasonably available for review by Purchaser upon request. Purchaser expressly acknowledges that if there is a conflict between this MTA and the Third Party Terms, the Third Party Terms shall govern. Use of the Biological Materials may be subject to the intellectual property rights of a person or entity not party to this MTA, the existence of which rights may or may not be identified in the ASC catalog or website, and ASC makes no representation or warranty regarding the existence or the validity of such rights. Purchaser shall have the sole responsibility for obtaining any intellectual property licenses necessitated by its possession and use of the Biological Materials.

The use permitted under this MTA for Industry Sponsored Academic Research extends only to the academic research carried out at the non-profit organization and the non-profit organization’s employees. Any non-profit Purchaser using the Biological Materials in connection with Industry Sponsored Academic Research agrees to notify the industrial sponsor that any use of the Biological Materials by the industry sponsor will require a separate license from ASC and/or its Contributors and that ASC and/or its Contributors are under no obligation hereunder to license any Biological Materials to any such industry sponsor.

Warranty; Warranty Disclaimer

ASC warrants that (a) cells and microorganisms included in the ASC Material shall be viable upon initiation of culture for a period of thirty (30) days after shipment thereof from ASC and (b) any ASC Material other than cells and microorganisms shall meet the specifications on the applicable ASC Material product information sheet, certificate of analysis, and/or catalog description until the expiration date on the applicable ASC Material’s product label (such thirty (30) day period, or period until the expiration date, referred to herein as the “Warranty Period”). Purchaser’s exclusive remedy, and ASC’s sole liability, for breach of the warranties set forth in this paragraph is for ASC to, at ASC’s sole option, either (i) refund the fee paid to ASC for such ASC Material (exclusive of shipping and handling charges), or (ii) replace the ASC Material. The warranties set forth in this paragraph apply only if Purchaser handles and stores the ASC Material as described in the applicable ASC Material product information sheet. To obtain the exclusive remedy, Purchaser must report the lack of viability or non-conformation to specifications to ASC’s Technical Service Department within the applicable Warranty Period. Any expiration date specified on the ASC Material shipment documentation states the expected remaining useful life, but does not constitute a warranty or extend any applicable Warranty Period. Except as expressly provided above, the ASC Material and any technical information and assistance provided by ASC are provided as-is, without warranties of any kind, express or implied, including but not limited to any implied warranties of merchantability, fitness for a particular purpose, typicality, safety, accuracy and/or non-infringement.

Purchaser acknowledges that the ASC Material and any technical information and assistance provided by ASC are developed and provided exclusively for research purposes, and Purchaser agrees to use the same at its sole risk. Purchaser agrees that ASC and its Contributors will not be liable for any loss, claim or demand made by Purchaser, or made against Purchaser by any other party, due to or arising from the use of the ASC Material by Purchaser, except to the extent permitted by law when caused by the gross negligence or willful misconduct of ASC.

Limitation of Liability

In no event shall ASC or its Contributors be liable for any use of the Biological Material by Purchaser, for any loss, claim, damage, or liability, of whatever kind or nature, which may arise from or in connection with this MTA or the use, handling, storage, or disposal of the Biological Material. ASC’s liability to Purchaser for any claim related to or arising from this MTA or the Biological Material, whether in contract, warranty, tort, or otherwise, shall be limited to the amount paid by Purchaser for the Biological Material. In no event shall ASC be liable for any indirect, special, incidental, consequential, or punitive damages, including without limitation, loss of profits or loss of use, even if ASC has been advised of the possibility of such damages. The limitations of liability set forth in this MTA shall survive termination or expiration of this MTA for any reason.